UAE approves new COVID-19 treatment for ages 12 and above
The UAE Ministry of Health and Prevention (MoHAP) has approved the emergency use of Sotrovimab (Vir-7831) as a new treatment for COVID-19, making it the first country in the world to license and enable immediate patient use.
Endorsed by the US Food and Drug Administration, the new treatment, from globally-leading healthcare company GlaxoSmithKline (GSK) offers the prospect of reducing hospitalization for more than 24 hours and fatalities by as much as 85% when administered to patients as an early treatment for COVID-19.
The UAE has authorized the emergency use of the monoclonal antibody for the treatment of patients aged 12 years or older with mild to moderate COVID-19 disease who are at risk of progression to hospitalization or death.
In pre-clinical studies, Sotrovimab has demonstrated effectiveness as a monotherapy against widely circulating variants of the disease.
